The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | RESONATE: five-year follow-up of ibrutinib for CLL
The RESONATE phase III trial (NCT01578707) investigated whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression-free survival (PFS) as compared to treatment with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL). Alessandra Tedeschi, MD, of the Niguarda Cancer Center, Milan, Italy, discusses the results of a five-year follow-up of this study at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
